Coluracetam powde 135463-81-9 was initially manufactured in the year 2005 in Japan
by Mitsubishi Tanabe Pharma Corporation. The first experiment that was
done on this drug was to establish its ability to treat Alzheimer’s
disease.
Later on, BrainCells Inc. in-licensed the development of the coluracetam nootropics depot 135463-81-9 for development for
depressive disorder treatment. The research which involved over 100
people with serious anxiety and depression symptoms revealed the
supplement’s benefits in the relief of major depressive disorder (MDD).
The nootropic powder can be dissolved in fats and oils and this coluracetam
solubility makes it (the supplement) have higher potency as compared to
phenylpiracetam powder. Due to the high coluracetam solubility, the
drug is quickly effective as its takes about 30 minutes to reach
high-level plasma cells. As such, its dosage amount should be smaller
than that of the rest of the nootropics belonging to racetam class.
